In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Residual risk seen for death, postacute sequelae in third year after COVID-19 hospitalization
Jun 13, 2024
The risk for death remains significantly elevated in the third year, as is risk for incident postacute sequelae of COVID-19.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
4.0 percent of seniors had received dementia diagnosis in 2022
Jun 13, 2024
An increase in the percentage with a dementia diagnosis was seen with increasing age; a decrease was seen with an increasing education level.
Expert panel develops new definition of long COVID
Jun 11, 2024
A new proposed definition for Long COVID could help patients get the help they need, a new report from the National Academies of Sciences, Engineering and Medicine says.
The 5-Cog paradigm improves diagnosis, management of dementia
Jun 11, 2024
A threefold improvement was seen in dementia care actions with the 5-Cog paradigm, a culturally adept cognitive detection tool.
Systemic side effects of COVID-19 vaccine tied to greater nAB response
Jun 11, 2024
Each 1-degree Celsius increase in skin temperature after a dose was linked to a 1.8- and 3.1-fold higher neutralizing antibody response one and six months later.